Table 1. Clinicopathological characteristic according to B-cell lymphoma 2 expression.
| Characteristic | All patients (n = 1,124) | p-value | Characteristic | All patients (n = 1,124) | p-value | ||
|---|---|---|---|---|---|---|---|
| BCL2 negative (n = 519) No. (%) |
BCL2 positive (n = 605) No. (%) |
BCL2 negative (n = 519) No. (%) |
BCL2 positive (n = 605) No. (%) |
||||
| Mean age (yr)* | 51.46 ± 10.69 | 50.19 ± 10.33 | 0.045 | ER | < 0.001 | ||
| Age (yr) | 0.036 | Negative | 227 (43.7) | 40 (6.6) | |||
| < 50 | 222 (42.8) | 332 (54.9) | Positive | 292 (56.3) | 565 (93.4) | ||
| ≥ 50 | 297 (57.2) | 273 (45.1) | PR | < 0.001 | |||
| Breast operation | 0.821 | Negative | 294 (56.6) | 114 (18.8) | |||
| Breast conservation | 294 (56.6) | 339 (56.0) | Positive | 225 (43.4) | 491 (81.2) | ||
| Mastectomy | 225 (43.4) | 266 (44.0) | HER2 | < 0.001 | |||
| Axillary operation | 0.634 | Negative | 312 (60.1) | 444 (73.4) | |||
| No | 3 (0.6) | 5 (0.8) | Positive | 207 (39.9) | 161 (26.6) | ||
| SLNB | 307 (59.2) | 341 (56.4) | Ki-67 (%) | < 0.001 | |||
| ALND | 209 (40.3) | 259 (42.8) | <14 | 214 (41.4) | 383 (63.4) | ||
| T stage | 0.037 | ≥14 | 301 (58.2) | 218 (36.1) | |||
| T1 | 318 (61.3) | 415 (68.6) | Unknown | 4 (0.4) | 4 (0.5) | ||
| T2 | 179 (34.5) | 170 (28.1) | p53 | < 0.001 | |||
| T3–T4 | 22 (4.2) | 20 (3.3) | Negative | 177 (34.2) | 229 (37.9) | ||
| N stage | 0.211 | Positive | 130 (25.1) | 67 (11.1) | |||
| N0 | 331 (63.8) | 421 (69.6) | Unknown | 212 (40.6) | 309 (51.1) | ||
| N1 | 120 (23.1) | 123 (20.3) | EGFR | < 0.001 | |||
| N2 | 42 (8.1) | 32 (5.3) | Negative | 327 (63.0) | 537 (88.8) | ||
| N3 | 23 (4.4) | 24 (4.0) | Positive | 185 (35.6) | 49 (8.1) | ||
| Unknown | 3 (0.6) | 5 (0.8) | Unknown | 7 (1.4) | 19 (3.1) | ||
| Stage | 0.011 | CK5/6 | <0.001 | ||||
| I | 241 (46.4) | 340 (56.2) | Negative | 352 (67.8) | 367 (60.7) | ||
| II | 206 (39.7) | 199 (32.9) | Positive | 114 (22.0) | 50 (8.3) | ||
| III | 69 (13.3) | 61 (10.1) | Unknown | 53 (10.2) | 188 (31.0) | ||
| Unknown | 3 (0.6) | 5 (0.8) | Molecular subtypes | <0.001 | |||
| Multiplicity | 0.092 | Luminal A | 133 (25.6) | 327 (54.0) | |||
| One | 434 (83.6) | 506 (83.6) | Luminal B (HER2 negative) | 64 (12.3) | 93 (15.4) | ||
| Two | 41 (7.9) | 63 (10.4) | Luminal B (HER2 positive) | 107 (20.6) | 153 (25.3) | ||
| More than three | 44 (8.5) | 36 (6.0) | HER2 overexpression | 100 (19.3) | 8 (1.3) | ||
| Histologic grade (Nottingham Histologic Score system) | <0.001 | TNBC | 115 (22.2) | 24 (4.0) | |||
| Well | 114 (22.0) | 224 (37.0) | Neoadjuvant chemotherapy | 0.025 | |||
| Moderately | 245 (47.2) | 301 (49.8) | No | 455 (87.7) | 555 (91.7) | ||
| Poorly | 160 (30.8) | 80 (13.2) | Yes | 64 (12.3) | 50 (8.3) | ||
| LVI | 0.011 | Adjuvant chemotherapy | 0.028 | ||||
| No | 326 (62.8) | 422 (69.8) | No | 21 (4.0) | 11 (1.8) | ||
| Yes | 188 (36.2) | 182 (30.1) | Yes | 498 (96.0) | 592 (97.9) | ||
| Unknown | 5 (1.0) | 1 (0.2) | Unknown | 0 | 2 (0.3) | ||
| Perineural invasion | 0.126 | Recurrence | 0.008 | ||||
| No | 493 (95.0) | 573 (94.7) | No | 452 (87.1) | 554 (91.6) | ||
| Yes | 19 (3.7) | 30 (5.0) | Yes | 67 (12.9) | 51 (8.4) | ||
| Unknown | 7 (1.3) | 2 (0.3) | Death | 0.036 | |||
| No | 496 (95.6) | 590 (97.5) | |||||
| Yes | 23 (4.4) | 15 (2.5) | |||||
BCL2=B-cell lymphoma 2; SLNB=sentinel lymph node biopsy; ALND=axillary lymph node dissection; LVI=lymphovascular invasion; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2; EGFR=epidermal growth factor receptor; CK5/6= cytokeratin 5/6; TNBC=triple-negative breast cancer.
*Mean±SD.